On Monday, Stifel, a financial services firm, adjusted its stance on Tempus AI Inc (NASDAQ:TEM), downgrading the stock from Buy to Hold. The firm set a new price target of $65.00, up from the previous $45.00. The decision follows a period of significant volatility for the Tempus AI shares since their initial public offering (IPO) in June.
Tempus AI's stock has experienced a notable increase of approximately 100% since its market debut. According to Stifel's analysis, the company's valuation now stands well above its peers, trading at 12.5 times its projected 2025 sales. This is compared to 9.4 times for Natera Inc (NASDAQ:NTRA). and 4.6 times for Guardant Health (NASDAQ:GH).
The reassessment of Tempus AI's outlook is partly based on recent market performance, including a surge in stock price last week. This increase came after the company's third-quarter conference call, which hinted that the 2025 forecasts for Tempus AI's core business might be set lower than current market expectations in the next quarter.
Stifel's revised rating to Hold reflects a cautious approach amidst the company's changing market dynamics. The new price target is based on an approximately 9 times enterprise value to sales valuation. The firm's updated target also considers the potential revenue from the recently announced acquisition of Ambry Genetics by Tempus AI.
Investors and market watchers will be keeping a close eye on Tempus AI's performance and strategic moves, especially as the company navigates its post-IPO landscape and integrates its latest acquisition into its business model.
In other recent news, Tempus AI's third-quarter results exceeded market expectations, leading Needham to raise its stock price target from $47.00 to $56.00 and maintain its Buy rating. The company's acquisition of Ambry Genetics is seen as a strategic move that introduces immediate genomics capabilities and promises more significant opportunities in data and applications over time.
Tempus AI's CEO, Eric Lefkofsky, has deferred the settlement of approximately 4.47 million restricted stock units to a period between January 15, 2025, and March 15, 2025. The company has also invested $36 million in Personalis (NASDAQ:PSNL), Inc., acquiring shares and exercising warrants for additional stock.
Loop Capital and BofA Securities initiated coverage on Tempus AI with a Buy rating, while Piper Sandler started with a Neutral rating. Loop Capital raised the price target for Tempus AI shares to $57, maintaining a Buy rating.
Avacta Therapeutics has entered into a strategic collaboration with Tempus AI, aiming to utilize AI in advancing the development of oncology drugs. The partnership will provide Avacta access to Tempus's comprehensive multimodal datasets, which include primary tumor samples and associated clinical data from over 200,000 patients.
Finally, Tempus AI's Tempus ECG-AF device, which uses artificial intelligence to identify patients at higher risk of atrial fibrillation/flutter, recently received FDA clearance.
These are the most recent developments for Tempus AI.
InvestingPro Insights
Recent data from InvestingPro sheds additional light on Tempus AI Inc's (NASDAQ:TEM) current market position, offering valuable context to Stifel's downgrade. The stock's recent performance aligns with InvestingPro's observation of a "Significant return over the last week," with a notable 49.03% price total return in just one week. This rapid ascent has pushed Tempus AI to trade near its 52-week high, with the current price at 95.81% of its peak.
InvestingPro Tips highlight that Tempus AI "operates with a moderate level of debt" and its "liquid assets exceed short term obligations," which could provide some financial stability as the company grows post-IPO. However, it's crucial to note that analysts "do not anticipate the company will be profitable this year," aligning with the InvestingPro data showing a negative operating income of -$692.48 million for the last twelve months as of Q3 2024.
For investors seeking a more comprehensive analysis, InvestingPro offers 12 additional tips for Tempus AI, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.